Authors
Antonis Kattamis, Konstantinos Bistas, Vangelis Mitros, Efthalia Faidra Agiomavriti Stefanopoulou, Polyxeni Delaporta
Published in
Expert opinion on pharmacotherapy. Jul 19, 2026. Epub Jul 19, 2026.
Abstract
Thalassemia is a group of diverse genetic disorders with worldwide distribution that affects hemoglobin synthesis. Until recently, the therapeutic approach to thalassemia was symptomatic, relying on red blood cell transfusions, treatment of comorbidities and disease-related complications. However, novel therapeutic agents have recently been developed and are gradually being integrated into routine clinical practice.
One of the most promising agents is mitapivat (AG348), an oral pyruvate kinase activator that enhances the erythrocytic adenosine triphosphate (ATP) production. After series of preclinical and clinical studies, mitapivat has been suggested to be a safe and effective disease modifier for thalassemia. Large double blind randomized clinical trials have indicated that mitapivat may increase baseline hemoglobin levels, reduce transfusion burden, control ineffective erythropoiesis and hemolysis and improve quality of life.
Mitapivat presents as a potential game-changer in the management of patients with both α- and β-thalassemia, regardless of transfusion dependency. However, further post-marketing evidence is required, in order to evaluate mitapivat profile under real world conditions and routine clinical practice.
PMID:
42472450
Bibliographic data and abstract were imported from PubMed on 20 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0